Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tildrakizumab withdrawal in plaque psoriasis
NCT04339595Phase 4Terminated
- Sponsor
- Almirall
- Start
- Jan 2020
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of tildrakizumab in plaque psoriasis, sponsored by Almirall. Started Jan 2020; status: terminated.
02
Drugs
tildrakizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04339595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04339595.